Use este identificador para citar ou linkar para este item: https://www.arca.fiocruz.br/handle/icict/60750

Tipo de documento
Artigo
Direito Autoral
Acesso aberto
Coleções
Compartilhar

Estatísticas
Metadata
Mostrar registro completo

DATA SOURCES FOR DRUG UTILIZATION RESEARCH IN LATIN AMERICAN COUNTRIES: A CROSS-NATIONAL STUDY - DASDUR-LATAM STUDY
Lopes, Luciane Cruz et al. | Data do documento: 2021
Autor(es)
Lopes, Luciane Cruz
Salas, Maribel
Castro, Claudia Garcia Serpa Osorio de
Leal, Lisiane Freitas
Doubova, Svetlana Vladislavovna
Cañás, Martín
Dreser, Anahi
Acosta, Angela
Baldoni, Andre Oliveira
Bergamaschi, Cristiane de Cássia
Mota, Daniel Marques
Gómez Galicia, Diana Lizbeth
Sepúlveda-Viveros, Dino
Narvaez Delgado, Edgard
Lima, Elisangela da Costa
Vera Chandia, Felipe
Ferre, Felipe
Marin, Gustavo Henrique
Olmos, Ismael
Zimmermann, Ivan Ricardo
Fulone, Izabela
Roldán-Saelzer, Juan
Sánchez-Salgado, Juan Carlos
Castro Pastrana, Lucila Isabel
Souza, Luiz Júpiter Carneiro de
Beltrán, Manuel Machado
Silva, Marcus Tolentino
Mena, María Belén
Fonteles, Marta Maria de França
Urtasun, Martín Alejandro
Tarapués, Monica
Granja Hernández, Patricia
Medero, Natalia
Herrera-Comoglio, Raquel
Barberato-Filho, Silvio
Galvão, Taís Freire
Luiza, Vera Lucia
Santa-Ana-Tellez, Yared
Rodríguez-Tanta, Yesenia
Elseviers, Monique
Afiliação
University of Sorocaba. Pharmaceutical Science Graduate Course. Sorocaba, SP, Brazil.
Daiichi Sankyo, Inc. Clinical Safety and Pharmacovigilance. Basking Ridge, NJ, United States / University of Pennsylvania Perelman School of Medicine. Philadelphia, PA, United States.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Departamento de Política de Medicamentos e Assistência Farmacêutica. Rio de Janeiro, RJ, Brasil.
McGill University. Department of Epidemiology Biostatistics and Occupational Health. Montreal, QC, Canada / Lady Davis Institute. Centre for Clinical Epidemiology. Montreal, QC, Canada.
Mexican Institute of Social Security. Epidemiology and Health Services Research Unit CMN Siglo XXI. Mexico City, DF, Mexico.
Arturo Jauretche National University. Institute of Health Sciences. Florencio Varela, BA, Argentina / Federacion Médica de la Provincia de Buenos Aires. La Plata, BA, Argentina.
National Institute of Public Health. Centre for Health Systems Research. Cuernavaca, MOR, Mexico.
Universidad ICESI. Facultad de Ciencias Naturales. Departamento de Ciencias Farmacéuticas. Cali, Colombia.
Federal University of São João Del-Rei. Pharmaceutical Science Course. Divinopolis, MG, Brazil.
University of Sorocaba. Pharmaceutical Science Graduate Course. Sorocaba, SP, Brazil.
Brazilian Health Regulatory Agency. Fifth Board of Directors. Brasília, DF, Brazil.
Autonomous University of the State of Morelos. Pharmacy of Faculty. Cuernavaca, MOR, Mexico.
Autonomous University of Chile. School of Medicine. Santiago, Chile.
Sem afiliação.
Universidade Federal do Rio de Janeiro. School of Pharmacy. Rio de Janeiro, RJ, Brazil.
Pontifical Catholic University of Chile. Health Technology Assessment Unit. Santiago, Chile.
Federal University of Minas Gerais. School of Medicine. Belo Horizonte, MG, Brazil.
National University of La Plata. Faculty of Medicine. La Plata, BA, Argentina.
Vilardebo Hospital. Unit of Clinical Pharmacology. Montevidéu, Uruguay / State Health Services Administration. Montevidéu, Uruguay.
University of Brasilia. Department of Public Health. Brasília, DF, Brazil.
University of Sorocaba. Pharmaceutical Science Graduate Course. Sorocaba, SP, Brazil.
Institute of Public Health of Chile. Department National Medicines Agency. Pharmacovigilance Subdepartment. Santiago, Chile.
Hypermedic MX. Scientific Department. Mexico City, DF, Mexico.
University of the Americas Puebla. Department of Chemical and Biological Sciences. Cholula, PUE, Mexico.
Fundação Oswaldo Cruz. Fiocruz Brasília. Brasília, DF, Brasil.
National University of Colombia. Pharmaceutical Science. Bogota, Colombia.
University of Sorocaba. Pharmaceutical Science Graduate Course. Sorocaba, SP, Brazil.
Central University of Ecuador. Faculty of Medical Sciences. Quito, Ecuador.
Federal University of Ceara. Technological Development and Innovation in Medicines Graduate Course. Fortaleza, CE, Brazil.
Arturo Jauretche National University. Institute of Health Sciences. Florencio Varela, BA, Argentina / Federacion Médica de la Provincia de Buenos Aires. La Plata, BA, Argentina.
Central University of Ecuador. Faculty of Medical Sciences. Quito, Ecuador.
Humanistic Organization for Social Change. Quito, Ecuador.
National University of Cordoba. School of Medical Sciences. Cordoba, Argentina.
Vilardebo Hospital. Unit of Clinical Pharmacology. Montevidéu, Uruguay / State Health Services Administration. Montevidéu, Uruguay.
National University of Cordoba. School of Medical Sciences. Cordoba, Argentina.
University of Sorocaba. Pharmaceutical Science Graduate Course. Sorocaba, SP, Brazil.
University of Campinas. School of Pharmaceutical Sciences. Campinas, SP, Brazil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Departamento de Política de Medicamentos e Assistência Farmacêutica. Rio de Janeiro, RJ, Brasil.
Utrecht Institute of Pharmaceutical Sciences. Division of Pharmacoepidemiology & Clinical Pharmacology. Utrecht, Netherlands.
Social Security of Peru. Institute of Health and Technology Assessment and Research. Lima, Peru.
University of Antwerp. Centre for Research and Innovation in Care. Antwerp, Belgium / University of Antwerp. Centre for Research and Innovation in Care. Antwerpen, Belgium / University of Ghent. Department of Clinical Pharmacology. Antwerpen, Belgium.
Resumo em Inglês
Purpose: Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region. Methods: A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were characterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed. Results: We identified 125 data sources for DUR in nine LatAm countries. Thirtyeight (30%) of them were publicly and conveniently available; 89 (71%) were accessible with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data. Conclusions: Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medicationrelated problems that need further exploration
Palavras-chave em inglês
Cross-national
Drug utilization research
Latin America
Pharmacoepidemiology
 
DeCS
Farmacoepidemiologia
Controle de Medicamentos e Entorpecentes
Política Nacional de Medicamentos
Uso de Medicamentos
América Latina
Fonte de Informação
 
Editor
John Wiley & Sons Ltd
Referência
LOPES, Luciane C. et al. Data sources for drug utilization research in Latin American countries: a cross-national study: DASDUR-LATAM study. Pharmacoepidemiology and Drug Safety, [s. l.], v. 31, n. 3, p. 343–352, dez. 2021.
DOI
10.1002/pds.5404
ISSN
1099-1557